Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Sign Up to like & getrecommendations! Published in 2022 at "Liver Cancer"
DOI: 10.1159/000527175
Abstract: Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab… read more here.
Keywords: hepatocellular carcinoma; treated advanced; previously treated; tislelizumab ... See more keywords